Xgeva® (denosumab 120mg) – Updated recommendations for calcium monitoring related to the risk of severe symptomatic hypocalcaemia (SSH)

GlaxoSmithKline would like to provide updated recommendations for risk mitigation of severe symptomatic hypocalcaemia (SSH) associated with Xgeva®. Clinical manifestations of SSH associated with XGEVA® have been reported in the post-marketing setting, including QTc interval prolongation, tetany, seizures, coma and altered mental status. Fatal cases of SSH have also been reported. Monitoring of calcium levels is now recommended in all patients at baseline and during treatment, especially in the first weeks of initiating therapy. Please refer to the letter for more information.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.